Product Datasheet

LAG-3 Antibody (17B4) - BSA Free NBP1-97657

Unit Size: 50 ug

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Reviews: 2 Publications: 18

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP1-97657

Updated 3/10/2024 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications
Submit a review at www.novusbio.com/reviews/destination/NBP1-97657



NBP1-97657

Application Notes


LAG-3 Antibody (17B4) - BSA Free	
Product Information	
Unit Size	50 ug
Concentration	1.0 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Monoclonal
Clone	17B4
Preservative	0.02% Sodium Azide
Isotype	IgG1 Kappa
Purity	Protein A or G purified
Buffer	PBS, 10% glycerol
Target Molecular Weight	57.5 kDa
Product Description	
Description	See NBP2-80059 for clone 17B4 See NBP3-23442 for clone L4-PL33
Host	Mouse
Gene ID	3902
Gene Symbol	LAG3
Species	Human, Primate
Reactivity Notes	Primate reactivity reported in scientific literature (PMID: 32284611).
Specificity/Sensitivity	LAG-3 Antibody (17B4) recognizes the 30 aa extra-loop of the first N-terminal D1 domain of human LAG-3.
Immunogen	This LAG-3 Antibody (17B4) was prepared from synthetic peptide corresponding to 30 aa (GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY) from the first N-terminal D1 domain of human LAG-3 (lymphocyte activation gene-3).
Product Application Details	
Applications	Western Blot, ELISA, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin, Immunoprecipitation, Block/Neutralize
Recommended Dilutions	Western Blot 5 ug/mL, Flow Cytometry, ELISA, Immunohistochemistry 1:10 - 1:500, Immunocytochemistry/ Immunofluorescence 1:10 - 1:500, Immunoprecipitation 10 ug/mL, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen 1:150, Block/Neutralize




Blocking/neutralizing application reported in scientific literature (PMID: 29671649, PMID: 28935468)

Images


Flow Cytometry: LAG-3 Antibody (17B4) [NBP1-97657] - Analysis using the FITC conjugate of NBP1-97657. Tumor infiltrating lymphocytes (TILs) express LAG-3 (detected using LAG-3 (human), mAb (17B4).




Western Blot: LAG-3 Antibody (17B4) [NBP1-97657] - Lane 1: MW marker. Lane 2: LAG-3 (human):Fc (human).




Flow Cytometry: LAG-3 Antibody (17B4) [NBP1-97657] - Analysis using the FITC conjugate of NBP1-97657. LAG-3 staining in resting and PHA activated lymphocytes. Image submitted by a verified customer review.




Flow Cytometry: LAG-3 Antibody (17B4) [NBP1-97657] - Analysis using the FITC conjugate of NBP1-97657. Staining of LAG-3 on CD4+ and CD8+ subpopulations of tumour infiltrating lymphocytes (TILs) detected with LAG-3 (human), mAb (17B4) (FITC).




Immunohistochemistry-Paraffin: LAG-3 Antibody (17B4) [NBP1-97657] - LAG-3 in human tonsil tissue sample. Image submitted by a verified customer review.



Flow Cytometry: LAG-3 Antibody (17B4) [NBP1-97657] - Analysis using the FITC conjugate of NBP1-97657. LAG-3 expression on activated human peripheral blood mononuclear cells (PBMC) detected with LAG-3 (human), mAb (17B4) (FITC).Method: T lymphocytes from human PBMC are stimulated with 1 ug/mL of PHA for three days. Then, after seven days of culture, 3x10^6 three-days PHA-activated human PBMC are treated with LAG-3 (human), mAb (17B4) (FITC) or FITC coupled isotype-matched (IgG1) control MAb (used at a saturating dilution of 1:800 and 1:150 respectively) for 30 min. at 4C in RPMI 1640 and washed twice with 1X PBS. Stained cells are then analysed by FC [4].



Flow Cytometry: LAG-3 Antibody (17B4) [NBP1-97657] - Analysis using the FITC conjugate of NBP1-97657. Method: LAG-3 (human), mAb (17B4) (FITC) (10 ug/mL) (is preincubated with a specific peptide epitope (208b) or a control tetanus toxoid (TT) peptide at different molarities prior to staining of TILs.



Publications

Li K, Tandurella JA, Gai J et al. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy Cancer cell 2022-10-21 [PMID: 36306792] (IF/IHC, Human)

Rappold PM, Vuong L, Leibold J et al. A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear Cell Renal Cell Carcinoma Cancer discovery 2022-06-27 [PMID: 35758895]

El Halabi L, Adam J, Gravelle P et al. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma Clinical Lymphoma Myeloma and Leukemia 2020-11-01 [PMID: 33277223] (IF/IHC, Human)

Details:

Immunohistochemical analysis of biopsies from patients with classic Hodgkins lymphoma.

Macon-Lemaitre L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 2005-05-31 [PMID: 15885122]

Details:

Citation using the FITC format of this antibody.

Dummer R, Lebbe C, Atkinson V et al. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i Nat Med 2020-10-01 [PMID: 33020648]

Harper J, Gordon S, Chan C et Al. CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption Nat Med. [PMID: 32284611] (FLOW, Primate)

Pericart S, Tosolini M, Gravelle P et al. Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining Cancers (Basel) 2018-10-31 [PMID: 30384489] (IF/IHC, Human)

Details:

Citation using the FITC form of this antibody.

Sabins NC, Chornoguz O, Leander K et al. TIM-3 Engagement Promotes Effector Memory T Cell Differentiation of Human Antigen-Specific CD8 T Cells by Activating mTORC1 J. Immunol. 2017 Nov 10 [PMID: 29127145] (Flow, Human)

Wang J, Ti Y, Wang Y et al. LAG-3 Represents a Marker of CD4+ T Cells with Regulatory Activity in Patients with Bone Fracture. Immunol. Invest. 2018-04-19 [PMID: 29671649] (Human)

Ma QY, Huang DY, Zhang HJ et al. Function and regulation of LAG3 on CD4(+)CD25(-) T cells in non-small cell lung cancer Exp. Cell Res. 2017-09-19 [PMID: 28935468] (Human)

Casati C, Camisaschi C, Novellino L et al. Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation. J Immunol. 2008 Mar. [PMID: 18322184]

Triebel F, Hacene K, Pichon MF et al. A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett. 2006 Apr. [PMID: 15946792]

More publications at http://www.novusbio.com/NBP1-97657





Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112 USA

Phone: 303.730.1950 Toll Free: 1.888.506.6887

Fax: 303.730.1966

nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave Toronto, ON M8Z 4E6 Canada

Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402

canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449

Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com Technical Support: nb-technical@biotechne.com

Orders: nb-customerservice@bio-techne.com

General: novus@novusbio.com

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP1-97657

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

